Maternal HPV Infection and the Estimated Risks for Adverse Pregnancy Outcomes-A Systematic Review

Diagnostics (Basel). 2022 Jun 15;12(6):1471. doi: 10.3390/diagnostics12061471.

Abstract

Background: Human Papilloma Virus (HPV) represents the most prevalent genital infection in young women of reproductive age.

Objective: This systematic review aims to estimate the effect of HPV infection during pregnancy and assess the correlation between HPV and adverse pregnancy outcomes.

Materials and methods: The search strategy has been developed based on the PICOS framework: Population (pregnant women infected with HPV), Intervention (HPV infection confirmed by molecular tests), Comparator (pregnant women without HPV infection), Outcomes (adverse pregnancy outcomes) and Study design (observational studies). We searched PubMed, Web of Science, and Scopus databases on 8 January 2022 by using the following keywords: "HPV", "prematurity", "preterm birth", "miscarriage", "premature rupture of membranes", "adverse pregnancy outcome", "low birth weight", "fetal growth restriction", "pregnancy-induced hypertensive disorders", "preeclampsia". Selection criteria were HPV infection confirmed within maximum 2 years before pregnancy with a molecular test and adverse pregnancy outcomes. (Results: Although numerous studies are conducted on this topic, data are still controversial regarding identifying maternal HPV infection as a risk factor for adverse pregnancy outcomes. More prospective large cohort studies are needed to prove a causative relationship.

Keywords: HPV; fetal growth restriction; miscarriage; preeclampsia; premature rupture of membranes; preterm birth.

Publication types

  • Review

Grants and funding

This research received no external funding.